Emlino 25/5 Tablet

Emlino 25/5 Tablet সম্পর্কে

বাংলাদেশে Emlino 25/5 Tablet ট্যাবলেট হিসেবে পাওয়া যায়; এতে Empagliflozin + Linagliptin আছে (২৫ mg + ৫ mg)। এই ব্র্যান্ডের প্রস্তুতকারক The ACME Laboratories Ltd। Emlino 25/5-এর সাথে Empagliflozin + Linagliptin-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।

Empagliflozin + Linagliptin-এর ১৬টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত।

Emlino 25/5 Tablet কী?

Emlino 25/5 comes as a tablet with 25 mg + 5 mg of Empagliflozin + Linagliptin, from The ACME Laboratories Ltd. Thus, linagliptin increases the concentrations of active inc The doctor decides the dose and course.

Emlino 25/5-এর ব্যবহার

Empagliflozin is indicated to reduce. Ask your doctor whether it is right for your condition.

Emlino 25/5 কীভাবে ব্যবহার করবেন

Swallow the tablet with water. Emlino 25/5 is taken by mouth. Take Emlino 25/5 as your doctor tells you. If you miss a dose, ask your doctor or pharmacist what to do. Do not change the dose or stop early without asking your doctor.

Emlino 25/5-এর পার্শ্বপ্রতিক্রিয়া

The most common side effects are: urinary tract infection stuffy or runny nose and sore throat upper respiratory tract infection Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.

সতর্কতা ও নিরাপত্তা

Patients on this tablet may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis. If suspected, discontinue this tablet, evaluate and treat promptly. Pancreatitis : There have been reports of acute pancreatitis, including fatal pancreatitis. Tell your doctor about all the other medicines you take.

সাধারণ প্রশ্ন

What is Emlino 25/5 used for?

Empagliflozin is indicated to reduce. Ask your doctor whether it is right for your condition.

How should I take Emlino 25/5?

Swallow the tablet with water. Emlino 25/5 is taken by mouth.

What should I watch for while using Emlino 25/5?

The most common side effects are: urinary tract infection stuffy or runny nose and sore throat upper respiratory tract infection Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.

Who should be careful with Emlino 25/5?

Patients on this tablet may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis. If suspected, discontinue this tablet, evaluate and treat promptly.

নির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce ... Read moreThis is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

ফার্মাকোলজি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Empagliflozin: Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for the reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increasing urinary glucose excretion.   Linagliptin: Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output.

মাত্রা ও সেবনবিধি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Assess renal function before initiating and as clinically indicated. The recommended dose of this is 10 mg empagliflozin and 5 mg linagliptin once daily, taken in the morning, with or without food. Dose may be increased to 25 mg empagliflozin and 5 mg linagliptin once daily.

Pediatric Patients: The safety and effectiveness in pediatric patients have not been established.

Geriatric Patients: Higher incidence of adverse reactions related to volume depletion and reduced renal function.

Renal Impairment: Higher incidence of adverse reactions related to reduced renal function.

পার্শ্ব প্রতিক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

The most common side effects are:
  • urinary tract infection
  • stuffy or runny nose and sore throat
  • upper respiratory tract infection

গর্ভাবস্থায় ও স্তন্যদানকালে

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Advise females of the potential risk to a fetus, especially during the second and third trimesters. This is not recommended when breastfeeding.

সতর্কতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Pancreatitis: There have been reports of acute pancreatitis, including fatal pancreatitis. If pancreatitis is suspected, promptly discontinue this tablet.

Ketoacidosis: Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. If suspected, discontinue this tablet, evaluate and treat promptly. Before initiating this tablet, consider risk factors for ketoacidosis. Patients on this tablet may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis.

Volume Depletion: Before initiating this tablet, assess volume status and renal function in patients with impaired renal function, elderly patients, or patients on loop diuretics. Monitor for signs and symptoms during therapy.

Urosepsis and Pyelonephritis: Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated.

Hypoglycemia: Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating this tablet.

Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Serious, life-threatening cases have occurred in both females and males. Assess patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise. If suspected, institute prompt treatment.

Genital Mycotic Infections: Monitor and treat as appropriate.

Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, and exfoliative skin conditions) have occurred with empagliflozin and linagliptin. If hypersensitivity reactions occur, discontinue this tablet, treat promptly, and monitor until signs and symptoms resolve.

Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate.

Bullous Pemphigoid: There have been reports of bullous pemphigoid requiring hospitalization. Tell patients to report the development of blisters or erosions. If bullous pemphigoid is suspected, discontinue this tablet.

Heart Failure: Heart failure has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of this tablet in patients who have known risk factors for heart failure. Monitor for signs and symptoms.

সংরক্ষণ

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

বিকল্প ব্র্যান্ড: Empagliflozin + Linagliptin

একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।

সব দেখুন ১৬ ব্র্যান্ড

ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।